Pfizer's third-generation non-small cell lung cancer treatment, Lorviqua, will be listed next month (September). As this drug can be used for non-small cell lung cancer that does not respond to ALK-positive first- and second-generation drugs, patients' treatment opportunities are expected to expand with registration. The HIRA announced on the 22nd that it will establish a new Lorviqua (second or more, chronic therapy) for non-small cell lung cancer in September while conducting an inquiry on the revision (draft) of the announcement according to drugs prescribed and administered to cancer patients. Detailed administration targets are progressive or metastatic patients who have been treated with ALK-positive and have be